Details
Structure visualisation
Entry information
| Complex | |
| AACDB_ID: | 2529 |
| PDBID: | 6NB3 |
| Chains: | HL_C |
| Organism: | Middle East respiratory syndrome-related coronavirus, Homo sapiens |
| Method: | EM |
| Resolution (Å): | 3.50 |
| Reference: | 10.1016/j.cell.2018.12.028 |
| Antibody | |
| Antibody: | LCA60 Fab |
| Antibody mutation: | No |
| INN (Clinical Trial): | |
| Antigen | |
| Antigen: | MERS-CoV Spike glycoprotein |
| Antigen mutation: | No |
| Durg Target: | |
Sequence information
Antibody
Heavy Chain: H
Mutation: NULL
| >6NB3_H|Chain C[auth D], D[auth H]|LCA60 heavy chain|Homo sapiens (9606) EVQLLESGGGLVKPGGSLRLSCEASGLTFSNVWMSWVRQAPGKGLEWVGRIKRKSEGATTDYGAPVKGRFTLSRDDSKNTVYLQMNSLKIDDTAVYYCSTLTRGGDVWSSSYYFDYWGQGALVTVSS |
Light Chain: L
Mutation: NULL
| >6NB3_L|Chain B[auth E], E[auth L]|LCA60 light chain|Homo sapiens (9606) QSALTQPASVSGSPGQSITISCTGTSSDVGTYDLVSWYQQHPGKSPKLMIYADIKRPSGVSHRFSGSKSGNTASLTISGLQSADEADYYCCLYAGSSTSVIFGGGTKVT |
Antigen
Chain: C
Mutation: NULL
| >6NB3_C|Chain A, F[auth B], G[auth C]|Spike glycoprotein|Middle East respiratory syndrome-related coronavirus (1335626) MGILPSPGMPALLSLVSLLSVLLMGCVAETGTVDVGPDSVKSACIEVDIQQTFFDKTWPRPIDVSKADGIIYPQGRTYSNITITYQGLFPYQGDHGDMYVYSAGHATGTTPQKLFVANYSQDVKQFANGFVVRIGAAANSTGTVIISPSTSATIRKIYPAFMLGSSVGNFSDGKMGRFFNHTLVLLPDGCGTLLRAFYCILEPRSGNHCPAGNSYTSFATYHTPATDCSDGNYNRNASLNSFKEYFNLRNCTFMYTYNITEDEILEWFGITQTAQGVHLFSSRYVDLYGGNMFQFATLPVYDTIKYYSIIPHSIRSIQSDRKAWAAFYVYKLQPLTFLLDFSVDGYIRRAIDCGFNDLSQLHCSYESFDVESGVYSVSSFEAKPSGSVVEQAEGVECDFSPLLSGTPPQVYNFKRLVFTNCNYNLTKLLSLFSVNDFTCSQISPAAIASNCYSSLILDYFSYPLSMKSDLSVSSAGPISQFNYKQSFSNPTCLILATVPHNLTTITKPLKYSYINKCSRLLSDDRTEVPQLVNANQYSPCVSIVPSTVWEDGDYYRKQLSPLEGGGWLVASGSTVAMTEQLQMGFGITVQYGTDTNSVCPKLEFANDTKIASQLGNCVEYSLYGVSGRGVFQNCTAVGVRQQRFVYDAYQNLVGYYSDDGNYYCLRACVSVPVSVIYDKETKTHATLFGSVACEHISSTMSQYSRSTRSMLKRRDSTYGPLQTPVGCVLGLVNSSLFVEDCKLPLGQSLCALPDTPSTLTPASVGSVPGEMRLASIAFNHPIQVDQLNSSYFKLSIPTNFSFGVTQEYIQTTIQKVTVDCKQYVCNGFQKCEQLLREYGQFCSKINQALHGANLRQDDSVRNLFASVKSSQSSPIIPGFGGDFNLTLLEPVSISTGSRSARSAIEDLLFDKVTIADPGYMQGYDDCMQQGPASARDLICAQYVAGYKVLPPLMDVNMEAAYTSSLLGSIAGVGWTAGLSSFAAIPFAQSIFYRLNGVGITQQVLSENQKLIANKFNQALGAMQTGFTTTNEAFQKVQDAVNNNAQALSKLASELSNTFGAISASIGDIIQRLDPPEQDAQIDRLINGRLTTLNAFVAQQLVRSESAALSAQLAKDKVNECVKAQSKRSGFCGQGTHIVSFVVNAPNGLYFMHVGYYPSNHIEVVSAYGLCDAANPTNCIAPVNGYFIKTNNTRIVDEWSYTGSSFYAPEPITSLNTKYVAPQVTYQNISTNLPPPLLGNSTGIDFQDELDEFFKNVSTSIPNFGSLTQINTTLLDLTYEMLSLQQVVKALNESYIDLKELGNYTYYNKGSGRENLYFQGGGGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGHHHHHHHH |
Interaction
1、Solvent accessible surface areas (SASA) were calculated (Naccess V2.1.1) for each residue in antibody and antigen, respectively. The residues with SASA loss in binding of more than 1Å2 were classified as interacting residues.
Interacting residues (ΔSASA based)
| L: THR25 SER26 SER27 ASP28 TYR32 LEU34 LEU92 ALA94 GLY95 SER96 SER97 THR98 H: TRP33 ARG50 LYS52 ARG103 VAL107 TRP108 SER109 SER110 TYR112 C: THR392 THR492 LYS493 PRO494 LEU495 LYS496 SER528 ILE529 PRO531 SER532 THR533 TRP535 GLU536 ASP537 ASP539 TYR540 TYR541 THR560 VAL561 ALA562 MET563 |
2、We defined interacting paratope-epitope residues by a distance cutoff of < 5Å . Two amino acids are considered as interacting residues if they have at least one atom within a distance of 5 Å from any atom.
Interacting residues (Atom distance based)
